Telix H1 2026 Results: Investor Webcast Notification

Telix to report H1 2026 results Aug 20 with investor webcast

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Telix plans to publish its half-year 2026 results on August 20, 2026, with an investor webcast and conference call. The update centers on a commercial radiopharmaceutical portfolio—Illuccix and Gozellix—and a deep pipeline including TLX591-Tx, TLX101-Tx, and TLX250-Tx. Guidance and trial progress could drive near-term sentiment and volatility ahead of the print.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Telix to report H1 2026 results on Aug 20, 2026; investor webcast to follow.</li><li>Investor webcast and conference call at 9:00 a.m. AEST; 7:00 p.m. EDT (Aug 19).</li><li>Telix&#039;s prostate imaging portfolio Illuccix/Gozellix; three late-stage TLX591-Tx, TLX101-Tx, TLX250-Tx.</li><li>Commercial-stage radiopharma with global operations across North America, Europe, APAC.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Telix Pharmaceuticals Limited (TLX)</strong>: Announces H1 2026 results date of Aug 20; earnings-driven event for TLX.</li><li><strong>Illuccix (N/A)</strong>: Telix prostate cancer imaging portfolio; available in 22 countries including the U.S.</li><li><strong>Gozellix (N/A)</strong>: FDA-approved kit; part of Telix imaging portfolio.</li></ul>
  </section>

  <section data-block="category">
    <h3>Earnings</h3>
    <p>Category: Earnings. The news centers on the timing of Telix’s H1 2026 results and related investor communications, a classic near-term event that can drive volatility depending on the quarter data and any guidance provided.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Aug 20, 2026 earnings release date could trigger volatility.</li><li>Data from TLX&#039;s TLX591-Tx, TLX101-Tx, TLX250-Tx pivotal trials may move sentiment.</li><li>FDA updates or progress for Illuccix/Gozellix could shift revenue expectations.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Half-year ended June 30, 2026.</li><li>Earnings release date: August 20, 2026; webcast at 9:00 a.m. AEST (7:00 p.m. EDT on Aug 19).</li><li>TLX is traded on ASX (TLX) and NASDAQ (TLX).</li><li>Illuccix is commercially available in 22 countries including the U.S.; Gozellix is FDA-approved.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term TLX price sensitivity hinges on the Aug 20 results; data or guidance could spark volatility within days.</p>
  </section>
</section>


<article>
  <p><strong>Telix Pharmaceuticals Limited</strong> (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will release its financial results for the half-year ended June 30, 2026 on Thursday August 20, 2026. An investor webcast and conference call will be held at <strong>9:00 a.m. AEST</strong> on Thursday August 20, 2026 (<strong>7:00 p.m. EDT</strong> Wednesday August 19, 2026). Participants can register for the webcast or teleconference at the following link: <a href="https://s1.c-conf.com/diamondpass/10056417-pz2402.html" rel="nofollow" target="_blank">https://s1.c-conf.com/diamondpass/10056417-pz2402.html</a></p>

  <section>
    <h2>Opening News Summary</h2>
    <p>This announcement confirms Telix's plan to disclose <strong>earnings</strong> and other <em>financial results</em> for the first half of 2026, solidifying TLX’s June 30, 2026 reporting period timelines. The investor webcast and conference call are scheduled to accompany the results release.</p>
  </section>

  <section>
    <h2>Event Details and Schedule</h2>
    <ul>
      <li><strong>Announcement date:</strong> July 31, 2026</li>
      <li><strong>Reporting period:</strong> <em>half-year ended June 30, 2026</em></li>
      <li><strong>Results release date:</strong> Thursday <strong>August 20, 2026</strong></li>
      <li><strong>Investor webcast & conference call:</strong> 9:00 a.m. AEST on August 20, 2026 (7:00 p.m. EDT on August 19, 2026)</li>
      <li><strong>Registration link:</strong> <a href="https://s1.c-conf.com/diamondpass/10056417-pz2402.html" rel="nofollow" target="_blank">https://s1.c-conf.com/diamondpass/10056417-pz2402.html</a></li>
    </ul>
  </section>

  <section>
    <h2>About Telix Pharmaceuticals Limited</h2>
    <p>Telix Pharmaceuticals ((ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease.</p>
  </section>

  <section>
    <h2>Product Portfolio and Clinical Pipeline</h2>
    <p>Telix's commercial franchise is anchored by its prostate cancer imaging portfolio: Illuccix&#xAE; (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S. and Gozellix&#xAE; (kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. Food and Drug Administration (FDA). The Company's late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials: <strong>TLX591-Tx</strong> (lutetium-177 (<sup>177</sup>Lu) rosopatamab tetraxetan) in prostate cancer, <strong>TLX101-Tx</strong> (<sup>131</sup>I-iodofalan) in recurrent glioblastoma, and <strong>TLX250-Tx</strong> (lutetium (<sup>177</sup>Lu) girentuximab tetraxetan) in kidney cancer, additionally complemented by a deep pipeline of next generation candidates.</p>
  </section>

  <section>
    <h2>Corporate Footprint</h2>
    <p>Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit <a href="https://www.telixpharma.com" rel="nofollow" target="_blank">www.telixpharma.com</a> or follow Telix on LinkedIn, X and Facebook.</p>
  </section>

  <section>
    <h2>Investor Relations and Media Contacts</h2>
    <ul>
      <li><strong>Investor Relations</strong><br><br><strong>Annie Kasparian</strong><br><a href="mailto:Annie.kasparian@telixpharma.com" rel="nofollow" target="_blank">Annie.kasparian@telixpharma.com</a><br><br><strong>Charlene Jaw</strong><br><a href="mailto:Charlene.jaw@telixpharma.com" rel="nofollow" target="_blank">Charlene.jaw@telixpharma.com</a><br><br></li>
      <li><strong>Media</strong><br><br><strong>Eliza Schleifstein</strong><br><a href="mailto:Eliza@schleifsteinpr.com" rel="nofollow" target="_blank">Eliza@schleifsteinpr.com</a><br><br></li>
    </ul>
  </section>

  <p><em>This announcement has been authorized for release by Telix Pharmaceuticals Limited’s Company Secretary, Shomalin Naidoo.</em></p>

  <section>
    <h2>Legal Notices and Forward-Looking Statements</h2>
    <p><em>Legal Notices</em></p>
    <p><em>Cautionary Statement Regarding Forward-Looking Statements. </em></p>
    <p><em>You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.</em></p>
    <p><em>The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.</em></p>
    <p><em>This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments...</em></p>
  </section>
</article>

Telix plans to publish its half-year 2026 results on August 20, 2026, with an investor webcast and conference call. The update centers on a commercial radiopharmaceutical portfolio—Illuccix and Gozellix—and a deep pipeline including TLX591-Tx, TLX101-Tx, and TLX250-Tx. Guidance and trial progress could drive near-term sentiment and volatility ahead of the print.

News insight

Telix H1 2026 Results: Investor Webcast Notification

AI summary

Sentiment rationale

Key facts

Earnings